nodes	percent_of_prediction	percent_of_DWPC	metapath
Fulvestrant—NR1H4—liver cancer	0.458	0.872	CbGaD
Fulvestrant—EPHX2—Sorafenib—liver cancer	0.309	0.968	CbGbCtD
Fulvestrant—ESR1—liver cancer	0.0675	0.128	CbGaD
Fulvestrant—NR1H4—bile duct—liver cancer	0.018	0.445	CbGeAlD
Fulvestrant—NR1H4—bile—liver cancer	0.0139	0.342	CbGeAlD
Fulvestrant—CYP3A4—Sorafenib—liver cancer	0.00633	0.0198	CbGbCtD
Fulvestrant—NR1H4—gall bladder—liver cancer	0.00385	0.0949	CbGeAlD
Fulvestrant—CYP3A4—Doxorubicin—liver cancer	0.00384	0.012	CbGbCtD
Fulvestrant—Embolism venous—Sorafenib—liver cancer	0.00138	0.0327	CcSEcCtD
Fulvestrant—Gastrointestinal symptom NOS—Sorafenib—liver cancer	0.00119	0.0281	CcSEcCtD
Fulvestrant—NR1H4—liver—liver cancer	0.00113	0.0278	CbGeAlD
Fulvestrant—EPHX2—liver—liver cancer	0.000986	0.0243	CbGeAlD
Fulvestrant—Injection site haemorrhage—Epirubicin—liver cancer	0.000957	0.0226	CcSEcCtD
Fulvestrant—Injection site haemorrhage—Doxorubicin—liver cancer	0.000886	0.0209	CcSEcCtD
Fulvestrant—Venous thromboembolism—Epirubicin—liver cancer	0.000877	0.0207	CcSEcCtD
Fulvestrant—ESRRA—liver—liver cancer	0.000863	0.0213	CbGeAlD
Fulvestrant—Venous thromboembolism—Doxorubicin—liver cancer	0.000812	0.0192	CcSEcCtD
Fulvestrant—ESR1—embryo—liver cancer	0.000767	0.0189	CbGeAlD
Fulvestrant—Blood bilirubin increased—Sorafenib—liver cancer	0.000738	0.0174	CcSEcCtD
Fulvestrant—Hepatic failure—Sorafenib—liver cancer	0.000564	0.0133	CcSEcCtD
Fulvestrant—Leukorrhea—Epirubicin—liver cancer	0.00055	0.013	CcSEcCtD
Fulvestrant—ESR2—liver—liver cancer	0.000518	0.0128	CbGeAlD
Fulvestrant—Vaginal moniliasis—Epirubicin—liver cancer	0.000511	0.0121	CcSEcCtD
Fulvestrant—Embolism venous—Epirubicin—liver cancer	0.000511	0.0121	CcSEcCtD
Fulvestrant—Leukorrhea—Doxorubicin—liver cancer	0.000509	0.012	CcSEcCtD
Fulvestrant—Pain in extremity—Sorafenib—liver cancer	0.000507	0.012	CcSEcCtD
Fulvestrant—Vulvovaginal candidiasis—Epirubicin—liver cancer	0.00049	0.0116	CcSEcCtD
Fulvestrant—Embolism venous—Doxorubicin—liver cancer	0.000473	0.0112	CcSEcCtD
Fulvestrant—Vaginal moniliasis—Doxorubicin—liver cancer	0.000473	0.0112	CcSEcCtD
Fulvestrant—Vulvovaginal mycotic infection—Epirubicin—liver cancer	0.000472	0.0112	CcSEcCtD
Fulvestrant—Breast disorder—Sorafenib—liver cancer	0.000458	0.0108	CcSEcCtD
Fulvestrant—Vulvovaginal candidiasis—Doxorubicin—liver cancer	0.000454	0.0107	CcSEcCtD
Fulvestrant—Vulvovaginal mycotic infection—Doxorubicin—liver cancer	0.000436	0.0103	CcSEcCtD
Fulvestrant—Vaginal discharge—Epirubicin—liver cancer	0.000424	0.01	CcSEcCtD
Fulvestrant—Pelvic pain—Epirubicin—liver cancer	0.000424	0.01	CcSEcCtD
Fulvestrant—Pelvic pain—Doxorubicin—liver cancer	0.000392	0.00927	CcSEcCtD
Fulvestrant—Vaginal discharge—Doxorubicin—liver cancer	0.000392	0.00927	CcSEcCtD
Fulvestrant—Infestation NOS—Sorafenib—liver cancer	0.00039	0.00923	CcSEcCtD
Fulvestrant—Infestation—Sorafenib—liver cancer	0.00039	0.00923	CcSEcCtD
Fulvestrant—Hepatobiliary disease—Sorafenib—liver cancer	0.000369	0.00873	CcSEcCtD
Fulvestrant—ESR1—liver—liver cancer	0.000355	0.00875	CbGeAlD
Fulvestrant—Haemoglobin—Sorafenib—liver cancer	0.000352	0.00833	CcSEcCtD
Fulvestrant—Haemorrhage—Sorafenib—liver cancer	0.00035	0.00829	CcSEcCtD
Fulvestrant—Vaginal haemorrhage—Epirubicin—liver cancer	0.000348	0.00824	CcSEcCtD
Fulvestrant—Connective tissue disorder—Sorafenib—liver cancer	0.000344	0.00814	CcSEcCtD
Fulvestrant—Vaginal haemorrhage—Doxorubicin—liver cancer	0.000322	0.00762	CcSEcCtD
Fulvestrant—Estradiol—ESR1—liver cancer	0.000321	0.446	CrCbGaD
Fulvestrant—Angiopathy—Sorafenib—liver cancer	0.000318	0.00752	CcSEcCtD
Fulvestrant—Immune system disorder—Sorafenib—liver cancer	0.000317	0.00748	CcSEcCtD
Fulvestrant—Injection site pain—Epirubicin—liver cancer	0.000316	0.00747	CcSEcCtD
Fulvestrant—Malnutrition—Sorafenib—liver cancer	0.000305	0.00721	CcSEcCtD
Fulvestrant—Vasodilation—Epirubicin—liver cancer	0.000293	0.00694	CcSEcCtD
Fulvestrant—Vasodilation procedure—Epirubicin—liver cancer	0.000293	0.00694	CcSEcCtD
Fulvestrant—Injection site pain—Doxorubicin—liver cancer	0.000292	0.00691	CcSEcCtD
Fulvestrant—Anaemia—Sorafenib—liver cancer	0.000282	0.00667	CcSEcCtD
Fulvestrant—Cough increased—Epirubicin—liver cancer	0.000282	0.00666	CcSEcCtD
Fulvestrant—Angioedema—Sorafenib—liver cancer	0.000279	0.00659	CcSEcCtD
Fulvestrant—Leukopenia—Sorafenib—liver cancer	0.000273	0.00646	CcSEcCtD
Fulvestrant—Blood bilirubin increased—Epirubicin—liver cancer	0.000273	0.00645	CcSEcCtD
Fulvestrant—Vasodilation—Doxorubicin—liver cancer	0.000272	0.00642	CcSEcCtD
Fulvestrant—Vasodilation procedure—Doxorubicin—liver cancer	0.000272	0.00642	CcSEcCtD
Fulvestrant—Bone pain—Epirubicin—liver cancer	0.000269	0.00637	CcSEcCtD
Fulvestrant—Cough—Sorafenib—liver cancer	0.000266	0.00629	CcSEcCtD
Fulvestrant—Inflammation—Epirubicin—liver cancer	0.000266	0.00629	CcSEcCtD
Fulvestrant—Musculoskeletal pain—Epirubicin—liver cancer	0.000261	0.00617	CcSEcCtD
Fulvestrant—Cough increased—Doxorubicin—liver cancer	0.000261	0.00616	CcSEcCtD
Fulvestrant—Myalgia—Sorafenib—liver cancer	0.00026	0.00614	CcSEcCtD
Fulvestrant—Arthralgia—Sorafenib—liver cancer	0.00026	0.00614	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.000258	0.0061	CcSEcCtD
Fulvestrant—Injection site reaction—Epirubicin—liver cancer	0.000256	0.00606	CcSEcCtD
Fulvestrant—Estradiol—CYP1A1—liver cancer	0.000256	0.356	CrCbGaD
Fulvestrant—Blood bilirubin increased—Doxorubicin—liver cancer	0.000252	0.00596	CcSEcCtD
Fulvestrant—Bone pain—Doxorubicin—liver cancer	0.000249	0.00589	CcSEcCtD
Fulvestrant—Infection—Sorafenib—liver cancer	0.000247	0.00585	CcSEcCtD
Fulvestrant—Inflammation—Doxorubicin—liver cancer	0.000246	0.00582	CcSEcCtD
Fulvestrant—Nervous system disorder—Sorafenib—liver cancer	0.000244	0.00577	CcSEcCtD
Fulvestrant—Skin disorder—Sorafenib—liver cancer	0.000242	0.00572	CcSEcCtD
Fulvestrant—Musculoskeletal pain—Doxorubicin—liver cancer	0.000242	0.00571	CcSEcCtD
Fulvestrant—Anorexia—Sorafenib—liver cancer	0.000237	0.00561	CcSEcCtD
Fulvestrant—Injection site reaction—Doxorubicin—liver cancer	0.000237	0.00561	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000227	0.00536	CcSEcCtD
Fulvestrant—Dyspnoea—Sorafenib—liver cancer	0.000222	0.00525	CcSEcCtD
Fulvestrant—Dyspepsia—Sorafenib—liver cancer	0.000219	0.00518	CcSEcCtD
Fulvestrant—Decreased appetite—Sorafenib—liver cancer	0.000216	0.00512	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Sorafenib—liver cancer	0.000215	0.00508	CcSEcCtD
Fulvestrant—Fatigue—Sorafenib—liver cancer	0.000215	0.00507	CcSEcCtD
Fulvestrant—Pain—Sorafenib—liver cancer	0.000213	0.00503	CcSEcCtD
Fulvestrant—Constipation—Sorafenib—liver cancer	0.000213	0.00503	CcSEcCtD
Fulvestrant—Hepatic failure—Epirubicin—liver cancer	0.000208	0.00493	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Sorafenib—liver cancer	0.000204	0.00481	CcSEcCtD
Fulvestrant—Hot flush—Epirubicin—liver cancer	0.0002	0.00473	CcSEcCtD
Fulvestrant—Menopausal symptoms—Epirubicin—liver cancer	0.000198	0.00469	CcSEcCtD
Fulvestrant—CYP3A4—liver—liver cancer	0.000198	0.00488	CbGeAlD
Fulvestrant—Urticaria—Sorafenib—liver cancer	0.000198	0.00468	CcSEcCtD
Fulvestrant—Abdominal pain—Sorafenib—liver cancer	0.000197	0.00465	CcSEcCtD
Fulvestrant—Body temperature increased—Sorafenib—liver cancer	0.000197	0.00465	CcSEcCtD
Fulvestrant—Hepatic failure—Doxorubicin—liver cancer	0.000193	0.00456	CcSEcCtD
Fulvestrant—Pain in extremity—Epirubicin—liver cancer	0.000187	0.00443	CcSEcCtD
Fulvestrant—Hot flush—Doxorubicin—liver cancer	0.000185	0.00438	CcSEcCtD
Fulvestrant—Menopausal symptoms—Doxorubicin—liver cancer	0.000184	0.00434	CcSEcCtD
Fulvestrant—Hypersensitivity—Sorafenib—liver cancer	0.000183	0.00434	CcSEcCtD
Fulvestrant—Asthenia—Sorafenib—liver cancer	0.000179	0.00422	CcSEcCtD
Fulvestrant—Pruritus—Sorafenib—liver cancer	0.000176	0.00416	CcSEcCtD
Fulvestrant—Pain in extremity—Doxorubicin—liver cancer	0.000173	0.0041	CcSEcCtD
Fulvestrant—Diarrhoea—Sorafenib—liver cancer	0.00017	0.00403	CcSEcCtD
Fulvestrant—Breast disorder—Epirubicin—liver cancer	0.000169	0.004	CcSEcCtD
Fulvestrant—Dizziness—Sorafenib—liver cancer	0.000165	0.00389	CcSEcCtD
Fulvestrant—Influenza—Epirubicin—liver cancer	0.000162	0.00383	CcSEcCtD
Fulvestrant—Vomiting—Sorafenib—liver cancer	0.000158	0.00374	CcSEcCtD
Fulvestrant—Rash—Sorafenib—liver cancer	0.000157	0.00371	CcSEcCtD
Fulvestrant—Dermatitis—Sorafenib—liver cancer	0.000157	0.00371	CcSEcCtD
Fulvestrant—Breast disorder—Doxorubicin—liver cancer	0.000157	0.0037	CcSEcCtD
Fulvestrant—Headache—Sorafenib—liver cancer	0.000156	0.00369	CcSEcCtD
Fulvestrant—Influenza—Doxorubicin—liver cancer	0.00015	0.00354	CcSEcCtD
Fulvestrant—Nausea—Sorafenib—liver cancer	0.000148	0.0035	CcSEcCtD
Fulvestrant—Infestation NOS—Epirubicin—liver cancer	0.000144	0.00341	CcSEcCtD
Fulvestrant—Infestation—Epirubicin—liver cancer	0.000144	0.00341	CcSEcCtD
Fulvestrant—Estradiol—ALB—liver cancer	0.000143	0.198	CrCbGaD
Fulvestrant—Urinary tract infection—Epirubicin—liver cancer	0.00014	0.00332	CcSEcCtD
Fulvestrant—Sweating—Epirubicin—liver cancer	0.000138	0.00327	CcSEcCtD
Fulvestrant—Hepatobiliary disease—Epirubicin—liver cancer	0.000136	0.00323	CcSEcCtD
Fulvestrant—Infestation NOS—Doxorubicin—liver cancer	0.000133	0.00316	CcSEcCtD
Fulvestrant—Infestation—Doxorubicin—liver cancer	0.000133	0.00316	CcSEcCtD
Fulvestrant—Haemoglobin—Epirubicin—liver cancer	0.00013	0.00308	CcSEcCtD
Fulvestrant—Urinary tract infection—Doxorubicin—liver cancer	0.00013	0.00307	CcSEcCtD
Fulvestrant—Haemorrhage—Epirubicin—liver cancer	0.000129	0.00306	CcSEcCtD
Fulvestrant—Hepatitis—Epirubicin—liver cancer	0.000129	0.00306	CcSEcCtD
Fulvestrant—Pharyngitis—Epirubicin—liver cancer	0.000129	0.00304	CcSEcCtD
Fulvestrant—Sweating—Doxorubicin—liver cancer	0.000128	0.00303	CcSEcCtD
Fulvestrant—Oedema peripheral—Epirubicin—liver cancer	0.000128	0.00302	CcSEcCtD
Fulvestrant—Connective tissue disorder—Epirubicin—liver cancer	0.000127	0.00301	CcSEcCtD
Fulvestrant—Hepatobiliary disease—Doxorubicin—liver cancer	0.000126	0.00298	CcSEcCtD
Fulvestrant—Haemoglobin—Doxorubicin—liver cancer	0.00012	0.00285	CcSEcCtD
Fulvestrant—Hepatitis—Doxorubicin—liver cancer	0.00012	0.00283	CcSEcCtD
Fulvestrant—Haemorrhage—Doxorubicin—liver cancer	0.00012	0.00283	CcSEcCtD
Fulvestrant—Pharyngitis—Doxorubicin—liver cancer	0.000119	0.00281	CcSEcCtD
Fulvestrant—Oedema peripheral—Doxorubicin—liver cancer	0.000118	0.00279	CcSEcCtD
Fulvestrant—Connective tissue disorder—Doxorubicin—liver cancer	0.000118	0.00278	CcSEcCtD
Fulvestrant—Angiopathy—Epirubicin—liver cancer	0.000117	0.00278	CcSEcCtD
Fulvestrant—Immune system disorder—Epirubicin—liver cancer	0.000117	0.00277	CcSEcCtD
Fulvestrant—Malnutrition—Epirubicin—liver cancer	0.000113	0.00267	CcSEcCtD
Fulvestrant—Back pain—Epirubicin—liver cancer	0.000109	0.00258	CcSEcCtD
Fulvestrant—Angiopathy—Doxorubicin—liver cancer	0.000109	0.00257	CcSEcCtD
Fulvestrant—Immune system disorder—Doxorubicin—liver cancer	0.000108	0.00256	CcSEcCtD
Fulvestrant—Malnutrition—Doxorubicin—liver cancer	0.000104	0.00247	CcSEcCtD
Fulvestrant—Anaemia—Epirubicin—liver cancer	0.000104	0.00246	CcSEcCtD
Fulvestrant—Vertigo—Epirubicin—liver cancer	0.000101	0.00239	CcSEcCtD
Fulvestrant—Leukopenia—Epirubicin—liver cancer	0.000101	0.00239	CcSEcCtD
Fulvestrant—Back pain—Doxorubicin—liver cancer	0.000101	0.00239	CcSEcCtD
Fulvestrant—Cough—Epirubicin—liver cancer	9.84e-05	0.00233	CcSEcCtD
Fulvestrant—Anaemia—Doxorubicin—liver cancer	9.64e-05	0.00228	CcSEcCtD
Fulvestrant—Chest pain—Epirubicin—liver cancer	9.6e-05	0.00227	CcSEcCtD
Fulvestrant—Myalgia—Epirubicin—liver cancer	9.6e-05	0.00227	CcSEcCtD
Fulvestrant—Arthralgia—Epirubicin—liver cancer	9.6e-05	0.00227	CcSEcCtD
Fulvestrant—Anxiety—Epirubicin—liver cancer	9.56e-05	0.00226	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	9.53e-05	0.00225	CcSEcCtD
Fulvestrant—Vertigo—Doxorubicin—liver cancer	9.37e-05	0.00222	CcSEcCtD
Fulvestrant—Leukopenia—Doxorubicin—liver cancer	9.34e-05	0.00221	CcSEcCtD
Fulvestrant—Infection—Epirubicin—liver cancer	9.14e-05	0.00216	CcSEcCtD
Fulvestrant—Cough—Doxorubicin—liver cancer	9.1e-05	0.00215	CcSEcCtD
Fulvestrant—Nervous system disorder—Epirubicin—liver cancer	9.02e-05	0.00213	CcSEcCtD
Fulvestrant—Skin disorder—Epirubicin—liver cancer	8.94e-05	0.00211	CcSEcCtD
Fulvestrant—Hyperhidrosis—Epirubicin—liver cancer	8.89e-05	0.0021	CcSEcCtD
Fulvestrant—Myalgia—Doxorubicin—liver cancer	8.88e-05	0.0021	CcSEcCtD
Fulvestrant—Arthralgia—Doxorubicin—liver cancer	8.88e-05	0.0021	CcSEcCtD
Fulvestrant—Chest pain—Doxorubicin—liver cancer	8.88e-05	0.0021	CcSEcCtD
Fulvestrant—Anxiety—Doxorubicin—liver cancer	8.85e-05	0.00209	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	8.82e-05	0.00209	CcSEcCtD
Fulvestrant—Anorexia—Epirubicin—liver cancer	8.77e-05	0.00207	CcSEcCtD
Fulvestrant—Infection—Doxorubicin—liver cancer	8.46e-05	0.002	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Epirubicin—liver cancer	8.38e-05	0.00198	CcSEcCtD
Fulvestrant—Nervous system disorder—Doxorubicin—liver cancer	8.35e-05	0.00197	CcSEcCtD
Fulvestrant—Insomnia—Epirubicin—liver cancer	8.32e-05	0.00197	CcSEcCtD
Fulvestrant—Skin disorder—Doxorubicin—liver cancer	8.27e-05	0.00196	CcSEcCtD
Fulvestrant—Paraesthesia—Epirubicin—liver cancer	8.26e-05	0.00195	CcSEcCtD
Fulvestrant—Hyperhidrosis—Doxorubicin—liver cancer	8.23e-05	0.00195	CcSEcCtD
Fulvestrant—Dyspnoea—Epirubicin—liver cancer	8.2e-05	0.00194	CcSEcCtD
Fulvestrant—Anorexia—Doxorubicin—liver cancer	8.11e-05	0.00192	CcSEcCtD
Fulvestrant—Dyspepsia—Epirubicin—liver cancer	8.1e-05	0.00191	CcSEcCtD
Fulvestrant—Decreased appetite—Epirubicin—liver cancer	8e-05	0.00189	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Epirubicin—liver cancer	7.94e-05	0.00188	CcSEcCtD
Fulvestrant—Fatigue—Epirubicin—liver cancer	7.93e-05	0.00188	CcSEcCtD
Fulvestrant—Pain—Epirubicin—liver cancer	7.87e-05	0.00186	CcSEcCtD
Fulvestrant—Constipation—Epirubicin—liver cancer	7.87e-05	0.00186	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Doxorubicin—liver cancer	7.76e-05	0.00183	CcSEcCtD
Fulvestrant—Insomnia—Doxorubicin—liver cancer	7.7e-05	0.00182	CcSEcCtD
Fulvestrant—Paraesthesia—Doxorubicin—liver cancer	7.64e-05	0.00181	CcSEcCtD
Fulvestrant—Dyspnoea—Doxorubicin—liver cancer	7.59e-05	0.00179	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Epirubicin—liver cancer	7.52e-05	0.00178	CcSEcCtD
Fulvestrant—Dyspepsia—Doxorubicin—liver cancer	7.49e-05	0.00177	CcSEcCtD
Fulvestrant—Decreased appetite—Doxorubicin—liver cancer	7.4e-05	0.00175	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Doxorubicin—liver cancer	7.35e-05	0.00174	CcSEcCtD
Fulvestrant—Fatigue—Doxorubicin—liver cancer	7.34e-05	0.00174	CcSEcCtD
Fulvestrant—Urticaria—Epirubicin—liver cancer	7.31e-05	0.00173	CcSEcCtD
Fulvestrant—Pain—Doxorubicin—liver cancer	7.28e-05	0.00172	CcSEcCtD
Fulvestrant—Constipation—Doxorubicin—liver cancer	7.28e-05	0.00172	CcSEcCtD
Fulvestrant—Body temperature increased—Epirubicin—liver cancer	7.27e-05	0.00172	CcSEcCtD
Fulvestrant—Abdominal pain—Epirubicin—liver cancer	7.27e-05	0.00172	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Doxorubicin—liver cancer	6.96e-05	0.00165	CcSEcCtD
Fulvestrant—Hypersensitivity—Epirubicin—liver cancer	6.78e-05	0.0016	CcSEcCtD
Fulvestrant—Urticaria—Doxorubicin—liver cancer	6.76e-05	0.0016	CcSEcCtD
Fulvestrant—Abdominal pain—Doxorubicin—liver cancer	6.73e-05	0.00159	CcSEcCtD
Fulvestrant—Body temperature increased—Doxorubicin—liver cancer	6.73e-05	0.00159	CcSEcCtD
Fulvestrant—Asthenia—Epirubicin—liver cancer	6.6e-05	0.00156	CcSEcCtD
Fulvestrant—Pruritus—Epirubicin—liver cancer	6.51e-05	0.00154	CcSEcCtD
Fulvestrant—Diarrhoea—Epirubicin—liver cancer	6.29e-05	0.00149	CcSEcCtD
Fulvestrant—Hypersensitivity—Doxorubicin—liver cancer	6.27e-05	0.00148	CcSEcCtD
Fulvestrant—Asthenia—Doxorubicin—liver cancer	6.11e-05	0.00144	CcSEcCtD
Fulvestrant—Dizziness—Epirubicin—liver cancer	6.08e-05	0.00144	CcSEcCtD
Fulvestrant—Pruritus—Doxorubicin—liver cancer	6.02e-05	0.00142	CcSEcCtD
Fulvestrant—Vomiting—Epirubicin—liver cancer	5.85e-05	0.00138	CcSEcCtD
Fulvestrant—Diarrhoea—Doxorubicin—liver cancer	5.82e-05	0.00138	CcSEcCtD
Fulvestrant—Rash—Epirubicin—liver cancer	5.8e-05	0.00137	CcSEcCtD
Fulvestrant—Dermatitis—Epirubicin—liver cancer	5.8e-05	0.00137	CcSEcCtD
Fulvestrant—Headache—Epirubicin—liver cancer	5.76e-05	0.00136	CcSEcCtD
Fulvestrant—Dizziness—Doxorubicin—liver cancer	5.63e-05	0.00133	CcSEcCtD
Fulvestrant—Nausea—Epirubicin—liver cancer	5.46e-05	0.00129	CcSEcCtD
Fulvestrant—Vomiting—Doxorubicin—liver cancer	5.41e-05	0.00128	CcSEcCtD
Fulvestrant—Rash—Doxorubicin—liver cancer	5.37e-05	0.00127	CcSEcCtD
Fulvestrant—Dermatitis—Doxorubicin—liver cancer	5.36e-05	0.00127	CcSEcCtD
Fulvestrant—Headache—Doxorubicin—liver cancer	5.33e-05	0.00126	CcSEcCtD
Fulvestrant—Nausea—Doxorubicin—liver cancer	5.06e-05	0.0012	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	2.74e-05	0.000382	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—GSTA2—liver cancer	2.73e-05	0.00038	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—TP53—liver cancer	2.72e-05	0.000379	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	2.72e-05	0.000378	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—APC—liver cancer	2.7e-05	0.000375	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	2.69e-05	0.000374	CbGpPWpGaD
Fulvestrant—NR1H4—Generic Transcription Pathway—SERPINE1—liver cancer	2.65e-05	0.000369	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—EXOSC2—liver cancer	2.64e-05	0.000368	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—H2AFX—liver cancer	2.64e-05	0.000367	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—GSTA1—liver cancer	2.64e-05	0.000367	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—GSTM1—liver cancer	2.63e-05	0.000366	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—NAT2—liver cancer	2.61e-05	0.000363	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—IL6—liver cancer	2.6e-05	0.000362	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—CYCS—liver cancer	2.6e-05	0.000362	CbGpPWpGaD
Fulvestrant—CYP3A4—Metapathway biotransformation—NAT2—liver cancer	2.57e-05	0.000358	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	2.56e-05	0.000357	CbGpPWpGaD
Fulvestrant—ESR2—Generic Transcription Pathway—PPARG—liver cancer	2.56e-05	0.000357	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—GGT1—liver cancer	2.55e-05	0.000355	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—GOT1—liver cancer	2.55e-05	0.000355	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—RAF1—liver cancer	2.54e-05	0.000354	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IFT88—liver cancer	2.52e-05	0.000351	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	2.5e-05	0.000348	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—CYP1A1—liver cancer	2.49e-05	0.000347	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—MTOR—liver cancer	2.49e-05	0.000347	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—IL6—liver cancer	2.49e-05	0.000347	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—HPGDS—liver cancer	2.49e-05	0.000347	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—PSMA4—liver cancer	2.48e-05	0.000346	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—PSMD10—liver cancer	2.48e-05	0.000346	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—PIK3CB—liver cancer	2.48e-05	0.000345	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—MTOR—liver cancer	2.48e-05	0.000345	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—PPARG—liver cancer	2.47e-05	0.000344	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—HRAS—liver cancer	2.46e-05	0.000343	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	2.42e-05	0.000336	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of Telomerase—AKT1—liver cancer	2.35e-05	0.000327	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—PPARA—liver cancer	2.35e-05	0.000327	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—CDKN1B—liver cancer	2.33e-05	0.000324	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—MTHFR—liver cancer	2.33e-05	0.000324	CbGpPWpGaD
Fulvestrant—ESR2—Generic Transcription Pathway—SERPINE1—liver cancer	2.31e-05	0.000322	CbGpPWpGaD
Fulvestrant—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	2.3e-05	0.00032	CbGpPWpGaD
Fulvestrant—ESRRA—Generic Transcription Pathway—MYC—liver cancer	2.3e-05	0.00032	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CASP3—liver cancer	2.29e-05	0.000319	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—GSTP1—liver cancer	2.29e-05	0.000319	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PPARA—liver cancer	2.28e-05	0.000318	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—HMOX1—liver cancer	2.26e-05	0.000314	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	2.25e-05	0.000314	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CCND1—liver cancer	2.23e-05	0.000311	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—JUN—liver cancer	2.23e-05	0.00031	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—ALB—liver cancer	2.22e-05	0.00031	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PSMA4—liver cancer	2.22e-05	0.000309	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PSMD10—liver cancer	2.22e-05	0.000309	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CTNNB1—liver cancer	2.21e-05	0.000308	CbGpPWpGaD
Fulvestrant—CYP3A4—Metapathway biotransformation—GPX3—liver cancer	2.19e-05	0.000304	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—AKT1—liver cancer	2.17e-05	0.000303	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—MAPK14—liver cancer	2.17e-05	0.000302	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—GOT2—liver cancer	2.16e-05	0.0003	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—CDKN1A—liver cancer	2.15e-05	0.000299	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—ESR1—liver cancer	2.13e-05	0.000296	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	2.12e-05	0.000295	CbGpPWpGaD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—ALB—liver cancer	2.12e-05	0.000295	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—GSTM1—liver cancer	2.1e-05	0.000293	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—NR1H4—liver cancer	2.1e-05	0.000293	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—HPGDS—liver cancer	2.08e-05	0.00029	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—NR1I3—liver cancer	2.07e-05	0.000288	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.05e-05	0.000285	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—AKT1—liver cancer	2.04e-05	0.000284	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	2.04e-05	0.000284	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—CYP2E1—liver cancer	2.03e-05	0.000282	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—CYP1A1—liver cancer	1.99e-05	0.000278	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.96e-05	0.000273	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PIK3CG—liver cancer	1.95e-05	0.000272	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—VEGFA—liver cancer	1.95e-05	0.000271	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—PPARG—liver cancer	1.94e-05	0.00027	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	1.94e-05	0.00027	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—H2AFX—liver cancer	1.93e-05	0.000268	CbGpPWpGaD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—RAF1—liver cancer	1.91e-05	0.000266	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	1.9e-05	0.000265	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—CYCS—liver cancer	1.9e-05	0.000264	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PPARG—liver cancer	1.89e-05	0.000263	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—GGT1—liver cancer	1.86e-05	0.000259	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—GOT1—liver cancer	1.86e-05	0.000259	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—MTHFR—liver cancer	1.86e-05	0.000259	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	1.85e-05	0.000257	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	1.85e-05	0.000257	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	1.83e-05	0.000255	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PPARA—liver cancer	1.82e-05	0.000254	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—MYC—liver cancer	1.79e-05	0.000249	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	1.79e-05	0.000249	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—SERPINE1—liver cancer	1.75e-05	0.000243	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	1.75e-05	0.000243	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PIK3CD—liver cancer	1.72e-05	0.000239	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—PPARA—liver cancer	1.71e-05	0.000239	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—CYP2E1—liver cancer	1.7e-05	0.000236	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—ALB—liver cancer	1.7e-05	0.000236	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—H2AFX—liver cancer	1.68e-05	0.000234	CbGpPWpGaD
Fulvestrant—NR1H4—Generic Transcription Pathway—MYC—liver cancer	1.68e-05	0.000234	CbGpPWpGaD
Fulvestrant—CYP3A4—Metapathway biotransformation—CYP2E1—liver cancer	1.67e-05	0.000233	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—GSTP1—liver cancer	1.67e-05	0.000233	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—KRAS—liver cancer	1.65e-05	0.00023	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—HMOX1—liver cancer	1.65e-05	0.00023	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—KRAS—liver cancer	1.65e-05	0.000229	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.64e-05	0.000228	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	1.61e-05	0.000224	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—MAPK14—liver cancer	1.58e-05	0.00022	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—PPARA—liver cancer	1.56e-05	0.000218	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PIK3CG—liver cancer	1.56e-05	0.000218	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—GGT1—liver cancer	1.56e-05	0.000217	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—ESR1—liver cancer	1.55e-05	0.000216	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—SHC3—liver cancer	1.54e-05	0.000215	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—GSTM1—liver cancer	1.54e-05	0.000214	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—PIK3CA—liver cancer	1.51e-05	0.00021	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PPARG—liver cancer	1.51e-05	0.00021	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PIK3CB—liver cancer	1.5e-05	0.000208	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—PPARA—liver cancer	1.49e-05	0.000208	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	1.48e-05	0.000207	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	1.48e-05	0.000206	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—TP53—liver cancer	1.47e-05	0.000205	CbGpPWpGaD
Fulvestrant—ESR2—Generic Transcription Pathway—MYC—liver cancer	1.46e-05	0.000203	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—CYP1A1—liver cancer	1.46e-05	0.000203	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—HNF4A—liver cancer	1.43e-05	0.0002	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—PPARG—liver cancer	1.42e-05	0.000197	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—GSTP1—liver cancer	1.4e-05	0.000195	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—HRAS—liver cancer	1.4e-05	0.000195	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	1.38e-05	0.000192	CbGpPWpGaD
Fulvestrant—CYP3A4—Metapathway biotransformation—GSTP1—liver cancer	1.38e-05	0.000192	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—MAPK14—liver cancer	1.38e-05	0.000192	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PIK3CD—liver cancer	1.37e-05	0.000191	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	1.37e-05	0.000191	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—MTHFR—liver cancer	1.36e-05	0.000189	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—ALB—liver cancer	1.36e-05	0.000189	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—ESR1—liver cancer	1.35e-05	0.000188	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—IL6—liver cancer	1.34e-05	0.000186	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PPARA—liver cancer	1.33e-05	0.000186	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—PPARG—liver cancer	1.29e-05	0.00018	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—GSTM1—liver cancer	1.29e-05	0.000179	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—SERPINE1—liver cancer	1.28e-05	0.000178	CbGpPWpGaD
Fulvestrant—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	1.27e-05	0.000177	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	1.26e-05	0.000175	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—PSMA4—liver cancer	1.25e-05	0.000174	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—PSMD10—liver cancer	1.25e-05	0.000174	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—AKT1—liver cancer	1.24e-05	0.000173	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—AKT1—liver cancer	1.23e-05	0.000172	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—PPARG—liver cancer	1.23e-05	0.000172	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—CYP1A1—liver cancer	1.22e-05	0.00017	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	1.22e-05	0.00017	CbGpPWpGaD
Fulvestrant—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	1.2e-05	0.000168	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—FST—liver cancer	1.2e-05	0.000167	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.2e-05	0.000167	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PIK3CB—liver cancer	1.2e-05	0.000167	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—SERPINE1—liver cancer	1.16e-05	0.000162	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TRIO—liver cancer	1.14e-05	0.000159	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PIK3CG—liver cancer	1.14e-05	0.000159	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—SERPINE1—liver cancer	1.11e-05	0.000155	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—MYC—liver cancer	1.11e-05	0.000154	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PPARG—liver cancer	1.1e-05	0.000153	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CCR4—liver cancer	1.1e-05	0.000153	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	1.03e-05	0.000143	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PIK3CD—liver cancer	1e-05	0.00014	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—ALB—liver cancer	9.91e-06	0.000138	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PIK3CA—liver cancer	9.13e-06	0.000127	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—UGDH—liver cancer	9.12e-06	0.000127	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PIK3CB—liver cancer	8.75e-06	0.000122	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—ADAM17—liver cancer	8.66e-06	0.000121	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—EPT1—liver cancer	8.58e-06	0.000119	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—H2AFX—liver cancer	8.46e-06	0.000118	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PSMA4—liver cancer	8.14e-06	0.000113	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PSMD10—liver cancer	8.14e-06	0.000113	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—TAT—liver cancer	8.13e-06	0.000113	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—MYC—liver cancer	8.08e-06	0.000112	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—AKT1—liver cancer	7.67e-06	0.000107	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—PPARA—liver cancer	7.53e-06	0.000105	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—AKT1—liver cancer	7.46e-06	0.000104	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—MYC—liver cancer	7.37e-06	0.000103	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PIK3CA—liver cancer	7.3e-06	0.000102	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—MYC—liver cancer	7.04e-06	9.8e-05	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—MAPK14—liver cancer	6.95e-06	9.68e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PRKCE—liver cancer	6.31e-06	8.79e-05	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—PPARG—liver cancer	6.22e-06	8.66e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IGF2—liver cancer	5.98e-06	8.32e-05	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—AKT1—liver cancer	5.96e-06	8.3e-05	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—SERPINE1—liver cancer	5.61e-06	7.81e-05	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—AKT1—liver cancer	5.6e-06	7.8e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CSF2—liver cancer	5.58e-06	7.77e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CPT1B—liver cancer	5.53e-06	7.7e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GLUL—liver cancer	5.53e-06	7.7e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—H2AFX—liver cancer	5.5e-06	7.66e-05	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PIK3CA—liver cancer	5.33e-06	7.43e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—NR1H4—liver cancer	5.33e-06	7.42e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GSTA3—liver cancer	5.24e-06	7.3e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TERT—liver cancer	4.98e-06	6.93e-05	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—AKT1—liver cancer	4.88e-06	6.79e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GSTA4—liver cancer	4.79e-06	6.67e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GSTA2—liver cancer	4.67e-06	6.5e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—KDR—liver cancer	4.55e-06	6.34e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MAPK14—liver cancer	4.52e-06	6.29e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GSTA1—liver cancer	4.51e-06	6.27e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—NAT2—liver cancer	4.46e-06	6.2e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—F2—liver cancer	4.38e-06	6.1e-05	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—AKT1—liver cancer	4.36e-06	6.07e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—ALDOB—liver cancer	4.27e-06	5.95e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—APC—liver cancer	4.19e-06	5.84e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PIK3CG—liver cancer	4.19e-06	5.84e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CRABP1—liver cancer	4.08e-06	5.67e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—BRAF—liver cancer	3.94e-06	5.49e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PIK3CD—liver cancer	3.69e-06	5.13e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—SERPINE1—liver cancer	3.64e-06	5.07e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—HPGDS—liver cancer	3.56e-06	4.96e-05	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—MYC—liver cancer	3.55e-06	4.94e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—RAF1—liver cancer	3.29e-06	4.58e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MTOR—liver cancer	3.21e-06	4.47e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PIK3CB—liver cancer	3.21e-06	4.47e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PSMD10—liver cancer	3.18e-06	4.42e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PSMA4—liver cancer	3.18e-06	4.42e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GOT2—liver cancer	3.09e-06	4.3e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CDKN1B—liver cancer	3.01e-06	4.2e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CASP3—liver cancer	2.95e-06	4.11e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IL2—liver cancer	2.95e-06	4.11e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CYP2E1—liver cancer	2.9e-06	4.04e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CCND1—liver cancer	2.88e-06	4e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—JUN—liver cancer	2.87e-06	4e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CTNNB1—liver cancer	2.85e-06	3.97e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MMP9—liver cancer	2.79e-06	3.89e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CDKN1A—liver cancer	2.78e-06	3.87e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CYCS—liver cancer	2.72e-06	3.78e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MAPK8—liver cancer	2.72e-06	3.78e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GOT1—liver cancer	2.67e-06	3.71e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GGT1—liver cancer	2.67e-06	3.71e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—VEGFA—liver cancer	2.51e-06	3.49e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—STAT3—liver cancer	2.48e-06	3.46e-05	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—AKT1—liver cancer	2.46e-06	3.43e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GSTP1—liver cancer	2.39e-06	3.33e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—HMOX1—liver cancer	2.36e-06	3.29e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MYC—liver cancer	2.31e-06	3.21e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TGFB1—liver cancer	2.3e-06	3.2e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GSTM1—liver cancer	2.2e-06	3.06e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—KRAS—liver cancer	2.13e-06	2.97e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CYP1A1—liver cancer	2.09e-06	2.9e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PIK3CA—liver cancer	1.96e-06	2.73e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—MTHFR—liver cancer	1.95e-06	2.71e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PPARA—liver cancer	1.91e-06	2.66e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TP53—liver cancer	1.89e-06	2.64e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—HRAS—liver cancer	1.81e-06	2.52e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IL6—liver cancer	1.73e-06	2.41e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PIK3CG—liver cancer	1.63e-06	2.28e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—AKT1—liver cancer	1.6e-06	2.23e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PPARG—liver cancer	1.58e-06	2.2e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PIK3CD—liver cancer	1.44e-06	2e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—ALB—liver cancer	1.42e-06	1.97e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PIK3CB—liver cancer	1.25e-06	1.74e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PIK3CA—liver cancer	7.63e-07	1.06e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—AKT1—liver cancer	6.24e-07	8.68e-06	CbGpPWpGaD
